Addex Therapeutics Ltd (ADXN)

Market Cap	6.08M
Revenue (ttm)	2.24M
Net Income (ttm)	-12.34M
Shares Out	1.05M
EPS (ttm)	-0.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,056
Open	5.80
Previous Close	5.55
Day's Range	5.52 - 6.02
52-Week Range	5.10 - 45.60
Beta	1.75
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 29, 2023

About ADXN

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 24
• Stock Exchange: NASDAQ
• Ticker Symbol: ADXN

Financial Performance

In 2022, ADXN's revenue was 1.44 million, a decrease of -54.18% compared to the previous year's 3.15 million. Losses were -20.80 million, 35.5% more than in 2021.

Financial numbers in CHF